An Overview of Bright Minds Biosciences

 Bright Minds Biosciences is a diagnosing, small-cap company striving to make descendants of serotonin drugs. These drugs will focus on specific brain conditions that lead to mental health issues and neurological ailments. Serotonin is the essential hormone that controls feelings of happiness and well-being. Further, it lets nervous system cells, including brain cells, interface with each other.

The novel serotonergic and psychedelic compounds of Bright Minds are designed to give considerable therapeutic advantages with fewer side effects. They act for the next species of more constructive treatments. The first creation of psychedelic compounds such as psycilocybin, which is the psychedelic and psychoactive compound noticed in magic mushrooms, was useful against, for example, Major Depressive Disorder (MDD) but showed great side effects.

Business Structure

The business structure of Bright Minds Biosciences includes the following:

● Seizures and Pains

● Neuropsychiatry

● Channel of Compounds

Seizures and Pain

The 5-HT2A and 5-HT2C compounds or agonists that start a psychological response when merged with a receptor can let patients manage their pain better. Also, keeping the side effects from other treatments away.

The  5-HT2C compounds of this company play a major role in treating epilepsy (a disease that has affected around  60 million people around the world). Unfortunately, 40% of patients who have epilepsy resist taking the drug treatments they’re prescribed, leading to more seizures.

Neuropsychiatry

The compounds of Bright Minds Biosciences are created to treat major depressive disorder patients though it is resistant to certain serotonin re uptake inhibitors (SSRIs), also called antidepressants. Nasal ketamine(a powerful antidepressant that might be used as an anesthetic in higher dosage) might be given to such patients.

For MDD patients who can be medicated with SSRIs, this company’s drugs can reasonably be chosen as they will not lead to weight gain, worsening impulsivity, or worsening sleep (common SSRIs side effects).

There’s a structure on the cell’s surface known as a receptor. It responds especially to a certain neurotransmitter, antigen, hormone, or other substance. For example, a class of serotonin or 5-HT receptors is observed in the peripheral and central nervous systems. Nerve cells release the signaling molecules there and attach with receptors on other neurons, a procedure known as neurotransmission.

Channel of Compounds

This company is evaluating the efficiency of its drug compounds with the help of its seven programs, including 5-HT2C and  5-HT2A agonists. Four of these seven programs come in the later preclinical stage.

Management Team

Ian McDonald, CEO, and Director

Mr. Ian McDonald is an entrepreneur and a former Investment Banker. He had a senior role at the Canadian Investment Bank.

Dr. Revati Shreeniwas, MD, Chief Medical Officer

Before entering this industry, Dr. Revati Shreeniwas was a performing physician and presented at Columbia and Standford University faculty. She has spent the last two decades in the pharmaceutical industry as a physician-researcher.

Dr. Alan Kozikowski Ph.D., Chief Scientific Officer, and Director

Trained at Harvard, Michigan, and Berkely, Dr. Alan Kozikowski started his journey at the University of Pittsburgh as an organic chemist. Then, pursuing his interests in chemistry applied to biological problems, he moved to a position at Mayo Clinic.

Ryan Cheung, Chief Financial Officer

Ryan Cheung is the founder of Chartered Professional Accountants, MCPA Services, Inc.,  located in Vancouver, B.C.